Epocrates, Inc. (Epocrates) is a provider of mobile drug reference tools and electronic health records to healthcare professionals and interactive services to the healthcare industry. As of December 31, 2011, its user network consists of well over one million healthcare professionals, including approximately 340,000, or more than 50% of United States physicians. The Company offers its products on major United States mobile platforms, including Apple iOS, Android and BlackBerry. Epocrates operates in two segments: Subscriptions and Interactive Services, and Electronic Health Records. It uses brand names include DocAlert, Epocrates, Epocrates Honors, Epocrates ID, Epocrates Lab, Epocrates MedTools, Epocrates Rx, Epocrates Rx Pro, Epocrates Dx, Epocrates QuickSurvey, Epocrates QuickRecruit, Epocrates MedInsight, EssentialPoints and MedCafe. In October 2011, it launched a redesign of the drug reference tool to create a new platform that provides healthcare professionals.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:EPOC
CUSIPN/A
Phone+1-415-4163500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$291.75
Epocrates (NASDAQ:EPOC) Frequently Asked Questions
What is Epocrates' stock symbol?
Epocrates trades on the NASDAQ under the ticker symbol "EPOC."
What is the consensus analysts' recommendation for Epocrates?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epocrates in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Epocrates been receiving favorable news coverage?
News coverage about EPOC stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Epocrates earned a daily sentiment score of 0.13 on Accern's scale. They also gave press coverage about the company an impact score of 46.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Epocrates?
Shares of EPOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epocrates' stock price today?
One share of EPOC stock can currently be purchased for approximately $11.73.
How big of a company is Epocrates?
Epocrates has a market capitalization of $291.75 million.
How can I contact Epocrates?
Epocrates' mailing address is 50 Hawthorne, SAN FRANCISCO, CA 94105, United States. The company can be reached via phone at +1-415-4163500.
MarketBeat Community Rating for Epocrates (NASDAQ EPOC)
MarketBeat's community ratings are surveys of what our community members think about Epocrates and other stocks. Vote "Outperform" if you believe EPOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
